OBJECTIVE: In a previous, double-blind, placebo-controlled study, @entity1 with @entity1005 ( @entity1005 ) showed lower physiological response during script-driven traumatic imagery 1 week after receiving a single dose of @entity1169 given after the retrieval of a traumatic memory. We hypothesized that this effect would extend beyond 1 week using a modified treatment approach. METHOD: Twenty-eight @entity1 with @entity1005 read an account of their traumatic event once weekly for 6 consecutive weeks under the influence of open-label @entity1169 . One week and 4-months later, skin conductance, heart rate, and left corrugator electromyogram responses were measured while @entity1 engaged in script-driven mental imagery of their traumatic event. Results from the 22 study @entity1 were compared with results from treated and untreated @entity1 in a previously published trial. RESULTS: Most @entity1 in our study were classified as non- @entity1005 cases at posttreatment and follow-up according to a psychophysiological discriminant function analysis. Posttreatment skin conductance and heart rate responses of the current ( @entity1169 -treated) @entity1 were lower than those of placebo @entity1 from the previous study. No difference was observed between physiological responding measured posttreatment and at follow-up. CONCLUSIONS: Low physiological responding during script-driven traumatic imagery after treatment extends up to 4 months, demonstrating the durability of the treatment effect's. Limitations include the absence of a placebo-controlled group and lack of physiological baseline measures. Despite these limitations, results point to the need for future trials examining the clinical efficacy of trauma reactivation plus @entity1169 , as it has the potential to become a novel, cost- and time-effective treatment for @entity1005 .

Trauma reactivation plus XXXX is associated with durably low physiological responding during subsequent script-driven traumatic imagery.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity1005 :: ('MESH:D013313', 'Disease') :: ['posttraumatic stress disorder', 'PTSD'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol']
@entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']
